This pathway supports tumor immune evasion by masking and blocking the interactions of membrane proteins.2 The therapeutic vulnerability of this axis was highlighted in another recent study3 where UGCG inhibition (via eliglustat) synergized with anti–PD-1 therapy in tumor-bearing mice. The gene discussed is UGCG; the disease is neoplasm.